Methadone (MTD) Rapid Test

A Methadone MTD Rapid Test is a drug abuse screening device used to detect methadone in a urine sample. It is commonly used as a first-level screening tool in professional environments where fast, practical, and easy-to-read results are required. The Methadone Rapid Test by LARKSOIS Pharma is qualitative, meaning it indicates whether the urine specimen is above or below the product’s screening threshold. It does not measure the exact concentration of methadone in the specimen.

• Methadone has legitimate medical use, but it is also a controlled opioid medicine requiring careful supervision.
• A dedicated MTD urine test helps support workplace drug abuse screening, clinical toxicology screening, rehabilitation and recovery monitoring, opioid treatment compliance programs, forensic and institutional testing, and pre-employment or random testing where legally permitted.
• The LARKSOIS Pharma MTD Rapid Test provides a practical preliminary screening option for professional drug testing programs that require methadone-specific detection.

The 300ng/ml cut-off means the Methadone (MTD) Rapid Test is designed to screen urine specimens at this threshold. If methadone concentration in the urine specimen meets or exceeds the cut-off level, the test may show a presumptive positive result. If the concentration is below the cut-off, the test may show a negative result. Cut-off values help standardize screening interpretation, but results may still be influenced by specimen quality, collection timing, storage conditions, test handling, cross-reactivity, and reading time.

• The MTD Rapid Test by LARKSOIS Pharma works through a rapid immunoassay principle. A urine specimen is applied to the test device according to the product insert, and the result is read visually within the recommended time window.
• The result should always be checked with the control indicator to confirm that the test has run correctly.
• The test provides a qualitative result, meaning it indicates whether methadone is detected above or below the specified product cut-off.

Instructions

• A valid control indicator must appear
• A positive result is presumptive only
• A negative result does not always rule out exposure
• Results should be read only within the recommended time window
• Non-negative results should be confirmed through certified laboratory testing
• Testing should follow local laws, workplace policy, and professional protocols

Instructions

• Urine-based methadone drug abuse screening
• 300ng/ml cut-off level
• Rapid test method for preliminary detection
• Suitable for professional testing programs
• Simple visual result interpretation
• Useful for clinical, workplace, forensic, and rehabilitation settings
• Supports methadone-specific drug screening
• Suitable for international diagnostic supply
• Practical product format for routine screening workflows
• Supplied by LARKSOIS Pharma for global markets

The Methadone (MTD) Rapid Test by LARKSOIS Pharma can be used across multiple professional settings where preliminary methadone screening support is required.

Applications

• Workplace drug screening
• Clinical and toxicology screening
• Rehabilitation and recovery monitoring
• Opioid treatment compliance programs
• Forensic and institutional testing
• Pre-employment or random testing where legally permitted
• International diagnostic distribution
• Laboratory and professional screening workflows

The Methadone (MTD) Rapid Test works on an immunoassay-based principle. When the urine specimen is applied to the test device, it reacts with specific reagents designed for methadone screening.

Benefits

• Urine-based rapid screening format
• 300ng/ml methadone cut-off
• Designed for MTD drug screening
• Suitable for professional diagnostic use
• Supports fast preliminary results
• Useful for workplace, forensic, clinical, rehabilitation, and institutional workflows
• Applicable for laboratories, hospitals, diagnostic centers, and distributors
• Supports international drug screening requirements

The Methadone (MTD) Rapid Test is designed for urine specimens. Urine testing is widely used in drug screening because it is non-invasive, simple to collect, and suitable for routine professional testing programs.

Guidance

• Use urine specimen only
• Follow the product insert carefully
• Use clean sample collection procedures
• Treat all urine specimens as potentially biohazardous
• Read results only within the recommended time window
• Use confirmatory testing where required by clinical, legal, workplace, forensic, or institutional policy

Note

A rapid screening result should be considered preliminary unless confirmed by a validated laboratory method where required.

• The MTD rapid urine test plays an important role in drug-of-abuse screening because methadone is a controlled opioid medicine requiring careful monitoring in many professional settings.
• In professional testing programs, rapid screening helps identify samples that may require further laboratory evaluation.
• For global buyers, the Methadone MTD Rapid Test 300ng/ml is a useful product for diagnostic portfolios, drug testing panels, rehabilitation support, workplace safety programs, forensic screening, opioid treatment compliance, and institutional monitoring applications.

Steps

• Bring the test device and urine specimen to the recommended testing condition
• Open the sealed pouch only when ready to test
• Collect urine using a clean sample collection procedure
• Apply the urine specimen according to the product insert
• Wait for the test reaction to complete within the instructed time
• Read the result within the approved interpretation window
• Dispose of used materials according to laboratory safety rules

Note

The exact procedure must follow the official LARKSOIS Pharma product insert supplied with the Methadone (MTD) Rapid Test.

Positive

A positive or non-negative result suggests that methadone may be present in the urine specimen at or above the stated cut-off. Positive results are preliminary and should be confirmed using a recognized laboratory method where required.

Negative

A negative result suggests that methadone was not detected or was below the cut-off at the time of testing. A negative result does not always rule out exposure if sample quality, collection timing, or the detection window affects the result.

Invalid

If the valid control indicator does not appear, the test is invalid. The test should be repeated with a new device and fresh urine specimen according to the product insert.

Instructions

• Store in a cool and dry place
• Keep away from direct sunlight and moisture
• Do not freeze the test device
• Keep the pouch sealed until use
• Do not use damaged or opened packaging
• Do not use after the expiry date
• Follow the storage temperature mentioned on the product label

Note

Proper storage helps maintain the reliability and performance of the MTD urine rapid test.

Instructions

• For professional in-vitro screening use only
• Use urine specimen only as directed
• Do not reuse the test device
• Follow the product insert carefully
• Wear gloves and follow standard hygiene practices
• Handle all urine specimens as potentially infectious material
• Avoid using expired or damaged test kits
• Do not interpret results after the recommended reading time
• Confirm presumptive positive results with laboratory testing
• Follow applicable drug testing laws and reporting requirements

LARKSOIS Pharma provides professional diagnostic and pharmaceutical solutions for international healthcare and screening markets. The Methadone (MTD) Rapid Test is developed for buyers who require a practical, reliable, and globally suitable drug abuse screening product.

Advantages

• International-quality product approach
• Professional drug of abuse rapid test portfolio
• Suitable for bulk and institutional supply
• Practical urine-based screening format
• Distributor-friendly product range
• Focus on consistency, usability, and screening reliability
• Suitable for workplace, forensic, clinical, and rehabilitation markets